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Abstract
Background: To estimate the prognostic value of submaximal negative dobutamine stress
echocardiography (NDSE) on major cardiac events.
Methods and results: Patients with NDSE were analyzed in 2 cohorts based on predicted
maximal heart rate (PMHR) (< 85% or ≥ 85% PMHR) and were assessed for major adverse
cardiac events over 3 years. Of 756 patients with NDSE, 415 achieved ≥ 85% PMHR. Both
groups had comparable ejection fractions (EF) > 50% (80.6% vs. 81.9%, p = 0.66). The NsubDSE
group had higher rates of atrioventricular nodal blocker use (58.7% vs. 39.9%, p < 0.0001),
and diabetes (38.7% vs. 27.6%, p = 0.001). Kaplan-Meier survival analysis showed no
differences in freedom from cardiac death (98% vs. 98%, p = 0.88), nonfatal myocardial
infarction (94% vs. 94%, p = 0.85), or combined major cardiac events (81% vs. 78%,
p = 0.24). Diabetes and preserved ejection fraction were predictive of cardiac events in
a multi-variate analysis (p = 0.005).
Conclusions: In our study, NsubDSE carried a favorable prognosis. Diabetics were more
likely to have an NsubDSE and suffer from a cardiac event despite a preserved ejection
fraction. Hence further evaluation for coronary artery disease in this high risk cohort should be
pursued. (Cardiol J 2008; 15: 237–244)
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Introduction
Dobutamine stress echocardiography (DSE) is
well established as a safe, feasible, and accurate
modality for detection of myocardial ischemia and
prognostication in patients with known or suspec-
ted coronary artery disease, particularly when they
have limited exercise capacity [1–3]. Although the
adverse prognosis of chronotropic incompetence is
well established with exercise testing [4], the progno-
stic value of negative submaximal DSE (NsubDSE),
defined as achieving < 85% predicted maximal he-
art rate achieved (PMHR) has varied implications.
Some studies have suggested that patients with
NsubDSE have adverse outcomes similar to pa-
tients with inducible ischemia in selected popula-
tions [5, 6]; others have reported that patients
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undergoing major noncardiac surgery with NsubDSE
have excellent immediate outcomes (< 1–2% an-
nual events rates), comparable to patients with ne-
gative maximal DSE (NmaxDSE), as long as resting
wall-motion abnormalities are not present [7]. Sin-
ce published studies assessing long-term progno-
stic significance of NsubDSE have tended to either
exclude patients on beta-blockers [5], or have stu-
died selected high-risk populations [6], the progno-
stic implications of NsubDSE in an unselected pa-
tient population on beta-blockers or rate-slowing
calcium-channel blocker therapy is unknown. Also,
although double product has been felt to be unim-
portant with DSE, we are not aware of specific stu-
dies addressing this in patients with NsubDSE. Thus,
whether this parameter carries a different connota-
tion in this subset is unclear. Consequently, we so-
ught to determine the prognostic value and outco-
mes following NsubDSE in an unselected population.
Method
Population
This study was carried out at a large tertiary
care center involving an unselected patient popu-
lation including patients on beta-blocker and cal-
cium-channel blocker therapy. Between January 1,
1999, and December 31, 1999, consecutive patients
who underwent DSE were screened retrospective-
ly. Patients with a positive DSE, younger than
18 years-old, pregnant, mentally impaired, or who
refused to provide consent were excluded. Patients
who underwent very early revascularization (< 2 mon-
ths) after index-negative DSE were excluded, as in
these cases the clinical suspicion and/or ancillary
testing likely influenced the decision for angiogra-
phy. Moreover, the outcomes were altered early in
these patients by intervention, thus precluding
long-term analysis of NsubDSE in this subset. Only
the first event data was used for patients with more
than one event. After applying exclusion criteria,
756 patients with negative DSE formed the initial
screening group. The study was approved by and
the ethical standards were in accordance with the
Henry Ford Hospital Institutional Review Board
(Detroit, MI).
Dobutamine stress
echocardiography protocol
Images were obtained in the parasternal long
axis and short axis, apical 4-axis, 2-axis, and apical
long axis at baseline, and after each incremental
dose of dobutamine. Images were digitally stored
at baseline, low, intermediate, and high doses to
facilitate quad screen display and analysis. Recovery
images were also obtained and stored on videota-
pe. In case of suboptimal digital capture quality,
a tape review was performed for interpretation.
Heart rate, blood pressure, and 12-lead electrocardio-
grams were recorded at baseline and monitored
through each stage. Dobutamine was initiated at
a dose of 10 µg/kg/min and increased at 3-min inte-
rvals to 20, 30, and up to a maximum of 40 mg/
/kg/min. Per our lab protocol, atropine is injected
(observing standard precautions and contraindica-
tions at 0.2 mg dose increments every minute, up
to a total dose of 2 mg) if a ≥ 85% age-PMHR or an
absolute heart rate of ≥ 100 has not been reached
after a 3-min infusion of dobutamine at 20 mg/
/kg/min. The test was terminated at the completion
of the protocol or with the development of signifi-
cant ischemic ST-segment shifts, intolerable symp-
toms, ventricular tachycardia, symptomatic hypo-
tension (or SBP < 90 mm Hg), or severe hyper-
tension (> 220/110 mm Hg). A normal DSE was
defined as having a normal contractile response with
dobutamine regardless of resting wall-motion ab-
normalities. An NsubDSE was defined by failure to
achieve a PMHR of ≥ 85%, but showing normal seg-
mental augmentation with dobutamine regardless
of the presence or absence of resting wall-motion
abnormalities. Visual assessment of wall motion
was accomplished using the following format: nor-
mal, hypokinetic, akinetic, and dyskinetic. The ASE
standard 16-segment models were used for the re-
porting of wall motion. Ejection fraction (EF) esti-
mation was based on visual assessment and an EF
≥ 50% was defined as normal.
Electrocardiograms were designated as ische-
mic with the presence of ≥ 1 mm of horizontal or
downsloping ST-segments 80 ms after the J-point,
or if there was ≥ 1 mm ST-segment elevation in
leads without significant Q-waves at baseline. Pa-
tients with a positive stress EKG but normal peak
wall motion were considered to have negative DSE,
and were part of the study group.
Endpoints and definitions
Individual major adverse cardiac events
(MACE) assessed were cardiac death, nonfatal
myocardial infarction (MI), and revascularization.
Individual endpoints and combined MACE utilizing
all 3 events were assessed. Patients were also fol-
lowed up for unstable angina (USA). The follow-up
period for reporting outcomes was 36 months. MI
was defined by CK elevation more than twice the
upper limit of normal, or troponin elevation above
the upper limit of normal in the setting of chest pain,
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or other clinical signs/symptoms suggesting cardiac
ischemia. Cardiac death was documented as death
related to MI (ST-elevation myocardial infarction
or non-ST-elevation myocardial infarction), conge-
stive heart failure, sudden cardiac death, arrhyth-
mias, or any event that was felt related to a cardiac
cause. Revascularization included any percutaneous
intervention or coronary artery bypass graft
(CABG) surgery. USA was defined as an accelera-
ted pattern of chest pain, with increased frequen-
cy, longer duration, decreased response to medical
therapy, occurrence at rest, or new onset chest pain.
Hypertension was defined as office visit docu-
mentation of history of hypertension, or being on
antihypertensive therapy. Diabetes mellitus (DM)
was present if there was documentation of DM in
an office note, or the patient was on antihypergly-
cemics (oral medication or insulin). Hypercholeste-
rolemia was present if office notes mentioned hi-
story of hyperlipidemia or if the patient was on an
anti-lipid medication. Heart failure (HF) was defined
as the presence of a history of systolic or diastolic
HF and/or left ventricular EF < 50% in the medical
record. Coronary artery disease (CAD) was defined
as a history of previous MI/angina or history of per-
cutaneous coronary intervention (PCI) or CABG.
The study was approved by the local bioethical
committee and all patients gave their informed consent.
Statistical analysis
A descriptive analysis was performed, compa-
ring baseline clinical and demographic characteri-
stics between the NmaxDSE (≥ 85% PMHR) and
NsubDSE (< 85% PMHR) patient groups. The two-
sample t-test for continuous variables and c2 test for
categorical variables were used. Kaplan-Meier ana-
lysis was used to create freedom-from-event curves
for individual major clinical outcomes (nonfatal MI,
cardiac death, revascularization), and combined
MACE. Cox regression analysis was used to deter-
mine predictors of cardiac death or nonfatal MI for
both the NsubDSE and NmaxDSE cohorts. All the
statistical analyses were performed using the SAS
software (version 8.2).
Results
Patient characteristics
A total of 756 patients had a negative DSE in
the specified time period, of which 341 patients
(45%) had NsubDSE studies and formed the study
population. The mean overall age was 71.4 ± 2.1
years and the mean overall follow-up time was
39.0 ± 18 months. About 80% of the patient popu-
lation including both the NDSE groups had prese-
rved left ventricular function (Table 1). Patients in
the NsubDSE groups were younger, with a higher
incidence of diabetes, hypertension, history of he-
art failure and prior percutaneous intervention, and
were more often on beta-blockers or calcium-chan-
nel blockers (Table 1). Primary indications for per-
forming DSE included chest pain, preoperative cle-
arance and evaluation for CAD. Reasons for DSE
termination included protocol completion and achie-
vement of maximum heart rate. The peak doses
of dobutamine achieved during the study were:
Table 1. Baseline characteristics of NsubDSE and NmaxDSE patients.
Variable NsubDSE (n = 341) NmaxDSE (n = 415) Group
(PMHR < 85%) (PMHR ≥ 85%) comparison (p)
Age (mean ±SD) 69.4 ± 12.9 73.0 ± 11.1 < 0.0001*
Gender (male) 42.2% (144/341) 40.7% (169/415) 0.68
Prior MI 24.6% (84/341) 19.3% (80/415) 0.08
Prior CABG 9.7% (33/341) 8.7% (36/415) 0.63
Prior PCI 14.7% (50/341) 8.7% (36/415) 0.01*
CAD 32.6% (111/341) 28.0% (116/415) 0.17
Tobacco use 28.4% (97/341) 23.4% (97/415) 0.11
Hypertension 91.5% (312/341) 86.3% (358/415) 0.02*
Hypercholesterolemia 52.8% (180/341) 49.6% (206/415) 0.39
History of HF 22.3% (76/341) 15.9% (66/415) 0.03*
Diabetes mellitus 39.0% (133/341) 27.7% (115/415) 0.001*
EF ≥ 50% 80.6% (275/341) 81.9% (339/414) 0.66
Beta-blockers/Ca-blockers 58.4% (199/341) 39.5% (164/415) < 0.0001*
*Statistically significant, p < 0.05; MI — myocardial infarction, CABG — coronary artery bypass grafting, PCI — percutaneous coronary intervention,
CAD — coronary artery disease, HF — heart failure, EF — ejection fraction, PMHR — predicted maximal heart rate
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4 patients received under 20 µg, 33 received 20 µg,
61 — 30 µg, and 238 patients received the peak dose
of 40 µg at the conclusion of the test. Dosing was
not specified in the stress reports in 5 patients.
About half of the NsubDSE cohort (48%) received
atropine based on the DSE protocol. The mean
double product was significantly lower in the
NsubDSE compared to NmaxDSE (16 473 ± 4901
vs. 19 230 ± 4648, p < 0.0001), and the mean ma-
ximum heart rate was also significantly different
between the 2 groups (110.9 ± 19.1 vs. 136.6 ±
± 11.3, p < 0.0001).
Outcomes
Figures 1–3 show the Kaplan-Meier survival
curves for freedom from non-fatal MI (93% vs. 94%,
p = 0.84), cardiac death (98% vs. 98%, p = 0.88),
and any revascularization (95% vs. 96%, p = 0.54)
between the NsubDSE and NmaxDSE groups at 36
months of follow-up, respectively. The freedom
from combined MACE rates between the 2 groups
at 36 months was also nonsignificant (89% vs. 90%,
p = 0.81) (Fig. 4). There were no significant event
rate differences between NsubDSE and NmaxDSE
patients who were subcategorized as those with an
Figure 1. Kaplan-Meier curves for freedom from non-
fatal myocadrial infarction based on achievement or lack
thereof at least 85% PMHR in negative DSE patients (log
rank p-value = 0.84); DSE — dobutamine stress echo-
cardiography, PMHR — predicted maximal heart rate.
Figure 2. Kaplan-Meier curves for freedom from car-
diac death based on achievement or lack thereof at
least 85% PMHR in negative DSE patients (log rank
p-value = 0.88); DSE — dobutamine stress echocardio-
graphy, PMHR — predicted maximal heart rate.
Figure 3. Kaplan-Meier curves for freedom from reva-
scularization based on achievement or lack thereof at
least 85% PMHR in negative DSE patients (log rank
p-value = 0.54); DSE — dobutamine stress echocardio-
graphy; PMHR — predicted maximal heart rate.
Figure 4. Kaplan-Meier curves for freedom from any
major adverse cardiac events based on achievement or
lack thereof at least 85% PMHR in negative DSE patients
(log rank p-value = 0.81); DSE — dobutamine stress echo-
cardiography; PMHR — predicted maximal heart rate.
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achieved PMHR < 70% versus those with a PMHR
of 70–84% (freedom from nonfatal MI 92% vs. 93%,
p = 0.83; cardiac death 98% vs. 98%, p = 0.36;
revascularization 97% vs. 94%, p = 0.94). When
NsubDSE patients were subcategorized as those
with double products < or ≥ 15 000 they had simi-
lar rates of nonfatal MI, cardiac death, revasculari-
zation, and combined MACE at 36 months (freedom
from nonfatal MI 94% vs. 92%, p = 0.30; cardiac
death 98% vs. 98%, p = 0.72; revascularization 93%
vs. 97%, p = 0.16).
There were 34 total all-cause deaths during
follow-up. Cox regression analysis to identify pre-
dictors of hard cardiac MACE (cardiac death or non-
fatal MI) was performed in both NsubDSE and
NmaxDSE groups. Older age, male gender, and hi-
story of heart failure or coronary artery disease
predicted events in NmaxDSE group whereas
history of diabetes mellitus and EF ≥ 50% predicted
events in the NsubDSE group.
A comparative analysis was performed betwe-
en both the study groups (> or £ 85% PMHR)
among patients who had cardiac events (cardiac
death or NFMI). Younger patients (69 ± 14.8 years
vs. 76.6 ± 8.7 years, p = 0.02) and those with dia-
betes mellitus were more likely not to achieve
a PMHR of 85% or greater (63.0% vs. 32.4%,
p = 0.015).
Discussion
This study shows that regardless of achieved
percentage of PMHR or double product; patients
with NsubDSE do not have increased MACE com-
pared to NmaxDSE patients over a 36-month
follow-up period. Overall, as long as there is a nor-
mal contractile response to dobutamine, these pa-
tients seem to have very low MACE rates (death,
nonfatal MI) over a 36-month follow-up period. Ne-
vertheless diabetics appear to be a distinct patient
population with worse outcomes, higher MACE
rates and an increased likelihood to have an NsubDSE
(Table 2).
An important aspect of our study, which needs
to be considered in drawing these conclusions, is
that 80.6% of NsubDSE and 81.9% of NmaxDSE
patients had a normal ejection fraction. Since EF is
a powerful predictor of cardiac mortality in patients
with coronary artery disease [8], it is not surprising
that the annualized cardiac death rate in both the
NsubDSE and NmaxDSE groups was about 0.6%,
with a 3-year event rate of 2%, which is similar to
prior published reports [9–11]. In our study, nonfa-
tal MI rates were 6% to 7% in both study groups
over 36 months, with annualized event rates of aro-
und 2%, which is also comparable to published re-
ports [9–13] for DSE. Similarly, revascularization
rates were comparably low over a 3-year follow-up
(4–5% over 3 years for both respective groups, non-
significant difference). We believe that the reason
for an EF > 50% to be a multivariate predictor of
cardiac events was likely confounding, due to the
large percentage of patients in the entire study po-
pulation with a normal ejection fraction.
Ballal et al. [5] reported that patients with
NsubDSE had adverse cardiac event rates similar
to positive DSE patients over a 28-month follow-
up. Their study reported a 31% cardiac event rate
in the NsubDSE group compared to a 36% event
rate in the positive DSE groups (p = NS), thereby
Table 2. Cox regression results for predicting any cardiac event (cardiac death or non-fatal MI) in patients
with NsubDSE.
Variable Univariable Multivariable Multivariable 95% hazard ratio
 p p hazard ratio  confidence limits
Age 0.907 0.820 1.004 0.973 1.035
Gender (male) 0.251 0.266 1.570 0.710 3.470
History of MI/CABG/PCI/CAD 0.494 0.632 0.807 0.336 1.938
Tobacco use 0.557 0.621 1.240 0.530 2.900
Hypertension 0.496 0.656 1.596 0.205 12.429
Hypercholesterolemia 0.958 0.951 1.026 0.462 2.277
History of HF 0.069 0.310 1.569 0.657 3.748
Diabetes mellitus 0.009* 0.005* 3.209 1.436 7.173
Ejection fraction ≥ 50% 0.022* 0.035* 0.379 0.154 0.933
Beta-blockers/Ca-blockers 0.934 0.990 1.005 0.455 2.222
*Statistically significant, p < 0.05; MI — myocardial infarction, CABG — coronary artery bypass grafting, PCI — percutaneous coronary intervention,
CAD — coronary artery disease, HF — heart failure
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concluding that an NsubDSE should be considered
nondiagnostic, necessitating further evaluation. The
key differences between their study and ours is that
they had a much higher risk population (higher in-
cidence of prior CAD, CABG, PCI), a much higher
incidence of left ventricular dysfunction (56%), and
exclusion of patients on beta-blockers, all of which
makes the 2 studies incomparable.
Another study focusing on DSE and chronotro-
pic incompetence (defined as < 85% PMHR) in
patients with peripheral arterial disease, Chaowa-
lit et al. [6] showed that NsubDSE was associated
with higher all-cause mortality and cardiovascular
morbidity, which is not surprising as this was a high-
risk cohort given significant concomitant periphe-
ral arterial disease [14]. However the study did not
focus on cardiac mortality as an endpoint and stu-
died a select high-risk patient population, much dif-
ferent to our study.
Our results show that despite being on beta-
-blockers or calcium-channel blockers, patients with
NsubDSE tests have similar outcomes compared to
patients with NmaxDSE. Previous studies have also
demonstrated that beta-blockers attenuate the
ischemic response in patients undergoing DSE,
particularly when the degree of stenosis is not se-
vere [15]. While withholding beta-blockers prior to
stress testing would be ideal in terms of maximi-
zing achievement of target heart rate, many refer-
ring physicians are hesitant to withhold beta-bloc-
kers. At our institution, withholding beta-blockers
or rate slowing calcium-channel blockers prior to
testing is not routine. This practice is consistent
with other reported studies [16–18]. Published data
indicating the safety, feasibility, and enhancement
of DSE diagnostic accuracy by using adjunctive atro-
pine during DSE can make physicians less inclined
to routinely withhold atrioventricular nodal bloc-
kers. About 48% of our study patients received ad-
junctive atropine. This is likely due to the fact that
over half the study population in our subDSE gro-
up was on atrioventricular-nodal blocking agents
(58% on beta-blockers or nondihydropyridine cal-
cium-channel blockers).
Race and dobutamine stress echocardiography
About half the study population comprised of
African Americans (AA) (421/801, 50%) and as de-
picted in our recent study of negative DSE patients
[19], AA patients had higher incidences of hyper-
tension (92% vs. 86%, p = 0.01) and left ventricu-
lar hypertrophy (71% vs. 50%, p < 0.001) compa-
red to Caucasian patients (CA). Stress variables
showed that AA patients had more hypertensive
responses (17% vs. 4%, p < 0.001), and fewer achie-
ved target heart rates (50% vs. 60%, p = 0.003)
despite a comparable rate of atrioventricular nodal
blocker use (50% vs. 51%, p = 0.746). It has been
shown that higher prevalence of diabetes mellitus,
hypertension, and other risk factors in AA lead to
dysfunction at the microvasculature level. Hence
we postulate that racial differences might explain
the higher frequency of subDSE in our study popu-
lation. The role of race in beta-receptor sensitivity
and response to chronotropic stimulus merits fur-
ther research with an added focus on pharmacoge-
netics of response to dobutamine in AA and CA
patients.
Although there is overwhelming evidence that
poor functional capacity is linked to increased ad-
verse outcomes, chronotropic incompetence with
DSE in a setting of atrioventricular nodal blockers
does not necessarily mean poor functional capacity
and adverse prognosis. As illustrated by prior au-
thors, being on beta-blocker therapy and having
a subDSE might simply reflect the therapeutic bra-
dycardic effect of these agents [7].
It is possible that NsubDSE can miss underly-
ing CAD and underestimate ischemic burden due
to decreased sensitivity from submaximal heart
rate, and we believe this is the reason for trend for
high rates of unstable angina and non-fatal MI in our
study. Tables 2 and 3 lists the predictors for car-
diac events (cardiac death or non-fatal MI) in the
NsubDSE and NmaxDSE groups obtained by Cox
regression analysis. As shown in Table 2, diabetes
mellitus and EF ≥ 50% were predictors for cardiac
events in the NsubDSE cohort.
Diabetes mellitus and
dobutamine stress echocargiography
Consistent with prior literature [20], in our
study diabetic patients were more likely to have
a cardiac event despite a NDSE. This is not surpri-
sing given the fact that diabetics (considered equi-
valent to having CAD) are known to carry an in-
creased cardiovascular risk particularly with docu-
mented CAD [21–23]. In our study, multivariate
analysis performed revealed diabetes mellitus to be
a significant predictor for any cardiac event in the
NsubDSE cohort (Table 2). Furthermore this high
risk cohort was more likely to have a subDSE se-
condary to under-achievement of PMHR of 85% or
higher (Table 1). Also, amongst patients who had
either cardiac death or non-fatal MI, diabetics were
less likely to achieve a PMHR of 85% or greater
(Table 4). Our results highlight the pitfalls of
NsubDSE in effectively risk stratifying diabetics
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thereby emphasizing the need for considering an
NsubDSE inconclusive in this patient subset and
proceeding with alternative definitive evaluation for
coronary artery disease.
Limitations of the study
This study had weaknesses inherent in retro-
spective analysis, which might include documenta-
tion inaccuracies and incomplete follow-up. The
difficulty in determining true unstable angina from
non-cardiac chest pain admissions in a retrospecti-
ve chart review might also have likely contributed
to the high rate of unstable angina in our patient
population. Patients who underwent very early
revascularization (< 2 months) after the index-ne-
gative DSE were excluded from the study; hence
we would be unable to comment on this group of
patients. A quantitative wall-motion scoring was not
performed and assessments of echocardiograms
were completed by multiple readers and based on
visual analysis.
Conclusions
Our study shows that NsubDSE is associated
with low MACE rate over a 36-month follow-up
period, regardless of the achieved heart rate or do-
uble product. Since the majority of our patients had
Table 3. Cox regression results for predicting any cardiac event (cardiac death or non-fatal MI)
in patients with NmaxDSE.
Variable Univariable Multivariable Multivariable 95% hazard ratio
p p hazard ratio confidence limits
Age 0.027* 0.068 1.033 0.998 1.070
Gender (male) 0.047* 0.298 1.453 0.719 2.935
History of MI/CABG/PCI/CAD < 0.001* 0.022* 2.427 1.135 5.189
Tobacco use 0.393 0.584 1.236 0.579 2.637
Hypertension 0.482 0.842 1.135 0.327 3.936
Hypercholesterolemia 0.801 0.466 0.774 0.389 1.540
History of HF 0.049* 0.525 1.327 0.555 3.178
Diabetes mellitus 0.566 0.897 1.049 0.511 2.151
EF ≥ 50% 0.100 0.920 0.957 0.404 2.265
Beta-blockers/Ca-blockers 0.262 0.583 1.212 0.611 2.406
*Statistically significant, p < 0.05; MI — myocardial infarction, CABG — coronary artery bypass grafting, PCI — percutaneous coronary intervention,
CAD — coronary artery disease, HF — heart failure, EF — ejection fraction
Table 4. Characteristics of patients who had either cardiac death or non-fatal MI in both groups.
Variable PMHR < 85% (n = 27) PMHR ≥ 85% (n = 37) p
Diabetes mellitus 17 (63.0%) 12 (32.4%) 0.015*
Hypertension 26 (96.3%) 34 (91.9%) 0.632
Hypercholesterolemia 15 (55.6%) 20 (54.1%) 0.905
Tobacco use 9 (33.3%) 11 (29.7%) 0.759
History of MI/CAD/CABG 12 (44.4%) 22 (59.5%) 0.235
Age 69.0 ± 14.8 76.6 ± 8.7 0.022*
Gender (male) 14 (51.9%) 20 (54.1%) 0.862
Race (black) 19 (79.2%) 24 (64.9%) 0.232
Beta-blocker 13 (48.1%) 13 (35.1%) 0.295
Ca-blocker 7 (25.9%) 8 (21.6%) 0.688
Baseline WMA 10 (37.0%) 12 (32.4%) 0.702
EF ≥ 50 18 (66.7%) 27 (73.0%) 0.586
Ischemic ECG change 4 (14.8%) 1 (2.7%) 0.153
*Statistically significant, p < 0.05; MI — myocardial infarction, CABG — coronary artery bypass grafting, CAD — coronary artery disease,
WMA — wall-motion abnormalities, EF — ejection fraction, PMHR — predicted maximal heart rate
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normal resting ejection fractions, our study findings
imply that unless clinically indicated, patients with
NsubDSE and normal resting ejection fractions
need not undergo further diagnostic evaluation, and
can be followed closely with all the continued ag-
gressive risk factor modification strategies. An
exception to this strategy would be diabetics in
whom an NsubDSE should be considered inconc-
lusive and further evaluation of CAD be carried out
as clinically indicated.
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